A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy.

Trial Profile

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 28 Aug 2012 Primary endpoint 'Pain-intensity' has not been met, based on results presented at 14th World Congress on Pain.
    • 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has not been met, based on results presented at 14th World Congress on Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top